Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
7.80
-0.20 (-2.50%)
Oct 6, 2026, 3:30 PM EDT - Market open
Verastem Employees
Verastem had 102 employees as of December 31, 2025. The number of employees increased by 24 or 30.77% compared to the previous year.
Employees
102
Change (1Y)
24
Growth (1Y)
30.77%
Revenue / Employee
$858,098
Profits / Employee
-$1,987,235
Market Cap
706.39M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 102 | 24 | 30.77% |
| Dec 31, 2024 | 78 | 5 | 6.85% |
| Dec 31, 2023 | 73 | 16 | 28.07% |
| Dec 31, 2022 | 57 | 9 | 18.75% |
| Dec 31, 2021 | 48 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Pharming Group | 407 |
| Wave Life Sciences | 317 |
| Olema Pharmaceuticals | 150 |
| Solid Biosciences | 121 |
| OmniAb | 89 |
| Shattuck Labs | 40 |
| Faeth Therapeutics | 29 |
VSTM News
- 23 hours ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 days ago - Verastem announces data from analysis of Phase 2 RAMP 201 trial - TheFly
- 4 days ago - Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026 - Business Wire
- 7 days ago - Verastem announces publication of RAMP 201 study in Gynecologic Oncology journal - TheFly
- 7 days ago - Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer - Business Wire
- 12 days ago - Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting - Business Wire
- 19 days ago - Verastem initiated with an Outperform at Wolfe Research - TheFly
- 22 days ago - Verastem Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts